Advertisement

Antiarrhythmic Drug Therapy in the Treatment of Acute and Chronic Atrial Flutter

  • Martina Amadori
    Affiliations
    Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, University of Bologna, Via Massarenti 9, Bologna 40138, Italy

    Cardiology Division, IRCCS AOU di Bologna, Bologna, via Massarenti 9, 40138 Bologna, Italy
    Search for articles by this author
  • Antonio Rapacciuolo
    Affiliations
    Department of Advanced Biomedical Science, University of Naples Federico II, Corso Umberto I 40, 80138 Naples, Italy

    Pharmacologic Area of AIAC (Associazione Italiana Aritmologia e Cardiostimolazione), Via Biagio Petrocelli 226, Rome 00173, Italy
    Search for articles by this author
  • Igor Diemberger
    Correspondence
    Corresponding author.
    Affiliations
    Department of Experimental, Diagnostic and Specialty Medicine, Institute of Cardiology, University of Bologna, Via Massarenti 9, Bologna 40138, Italy

    Cardiology Division, IRCCS AOU di Bologna, Bologna, via Massarenti 9, 40138 Bologna, Italy

    Pharmacologic Area of AIAC (Associazione Italiana Aritmologia e Cardiostimolazione), Via Biagio Petrocelli 226, Rome 00173, Italy
    Search for articles by this author
Published:August 24, 2022DOI:https://doi.org/10.1016/j.ccep.2022.05.006

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cardiac Electrophysiology Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Waldo A.
        Atrial flutter.
        in: Podrid P. Kowey P. Cardiac arrhythmia: mechanisms, diagnosis and management. Williams and Wilkens, Baltimore2001: 501-516
        • Saoudi N.
        • Cosio F.
        • Waldo A.
        • et al.
        Classification of atrial flutter and regular atrial tachycardia according to electrophysiologic mechanism and anatomic bases: a statement from a joint expert group from the Working Group of Arrhythmias of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology.
        J Cardiovasc Electrophysiol. 2001; 12: 852-866
        • Waldo A.L.
        Mechanisms of atrial flutter and atrial fibrillation: distinct entities or two sides of a coin?.
        Cardiovasc Res. 2002; 54: 217-229
        • Tomita Y.
        • Matsuo K.
        • Sahadevan J.
        • et al.
        Role of functional block extension in lesion-related atrial flutter.
        Circulation. 2001; 103: 1025-1030
        • Page P.L.
        • Plumb V.J.
        • Okumura K.
        • et al.
        A new animal model of atrial flutter.
        J Am Coll Cardiol. 1986; 8: 872-879
        • Cox J.L.
        • Canavan T.E.
        • Schuessler R.B.
        • et al.
        The surgical treatment of atrial fibrillation. II. Intraoperative electrophysiologic mapping and description of the electrophysiologic basis of atrial flutter and atrial fibrillation.
        J Thorac Cardiovasc Surg. 1991; 101: 406-426
        • Guichard J.B.
        • Naud P.
        • Xiong F.
        • et al.
        Comparison of atrial remodeling caused by sustained atrial flutter versus atrial fibrillation.
        J Am Coll Cardiol. 2020; 76: 374-388
        • Naccarelli G.V.
        • Lee K.S.
        • Gibson J.K.
        • et al.
        Electrophysiology and pharmacology of ibutilide.
        Am J Cardiol. 1996; 78: 12-16
        • Brugada J.
        • Katritsis D.G.
        • Arbelo E.
        • et al.
        2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).
        Eur Heart J. 2020; 41: 655-720
        • Page R.L.
        • Joglar J.A.
        • Caldwell M.A.
        • et al.
        2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society.
        J Am Coll Cardiol. 2016; 67: 1575-1623
        • Priori S.G.
        • Barhanin J.
        • Hauer R.N.
        • et al.
        Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology.
        Eur Heart J. 1999; 20: 174-195
        • Vitali Serdoz L.
        • Rittger H.
        • Furlanello F.
        • et al.
        Quinidine-A legacy within the modern era of antiarrhythmic therapy.
        Pharmacol Res. 2019; 144: 257-263
        • Capucci A.
        • Aschieri D.
        • Villani G.Q.
        Clinical pharmacology of antiarrhythmic drugs.
        Drugs Aging. 1998; 13: 51-70
        • Stambler B.S.
        • Wood M.A.
        • Ellenbogen K.A.
        Pharmacologic alterations in human type I atrial flutter cycle length and monophasic action potential duration. Evidence of a fully excitable gap in the reentrant circuit.
        J Am Coll Cardiol. 1996; 27: 453-461
        • Camm J.
        • Ward D.
        • Spurrell R.
        Response of atrial flutter to overdrive atrial pacing and intravenous disopyramide phosphate, singly and in combination.
        Br Heart J. 1980; 44: 240-247
        • Harrison D.C.
        Antiarrhythmic drug classification: new science and practical applications.
        Am J Cardiol. 1985; 56: 185-187
        • Buchanan L.V.
        • Kabell G.
        • Gibson J.K.
        Acute intravenous conversion of canine atrial flutter: comparison of antiarrhythmic agents.
        J Cardiovasc Pharmacol. 1995; 25: 539-544
        • Feld G.K.
        • Venkatesh N.
        • Singh B.N.
        Pharmacologic conversion and suppression of experimental canine atrial flutter: differing effects of d-sotalol, quinidine, and lidocaine and significance of changes in refractoriness and conduction.
        Circulation. 1986; 74: 197-204
        • Mugnai G.
        • Paolini C.
        • Cavedon S.
        • et al.
        Mexiletine for ventricular arrhythmias in patients with chronic coronary syndrome: a cohort study.
        Acta Cardiol. 2021; : 1-7https://doi.org/10.1080/00015385.2021.1926628
        • Sobiech M.
        • Lewandowski M.
        • Zajac D.
        • et al.
        Efficacy and tolerability of mexiletine treatment in patients with recurrent ventricular tachyarrhythmias and implantable cardioverter-defibrillator shocks.
        Kardiol Pol. 2017; 75: 1027-1032
        • Boriani G.
        • Capucci A.
        • Strocchi E.
        • et al.
        Flecainide acetate: concentration-response relationships for antiarrhythmic and electrocardiographic effects.
        Int J Clin Pharmacol Res. 1993; 13: 211-219
        • Follmer C.H.
        • Cullinan C.A.
        • Colatsky T.J.
        Differential block of cardiac delayed rectifier current by class Ic antiarrhythmic drugs: evidence for open channel block and unblock.
        Cardiovasc Res. 1992; 26: 1121-1130
        • Hindricks G.
        • Potpara T.
        • Dagres N.
        • et al.
        2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.
        Eur Heart J. 2021; 42: 373-498
        • Alboni P.
        • Botto G.L.
        • Baldi N.
        • et al.
        Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach.
        N Engl J Med. 2004; 351: 2384-2391
        • Boriani G.
        • Diemberger I.
        • Biffi M.
        • et al.
        Pharmacological cardioversion of atrial fibrillation: current management and treatment options.
        Drugs. 2004; 64: 2741-2762
        • Inoue H.
        • Yamashita T.
        • Usui M.
        • et al.
        Antiarrhythmic drugs preferentially produce conduction block at the area of slow conduction in the re-entrant circuit of canine atrial flutter: comparative study of disopyramide, flecainide, and E-4031.
        Cardiovasc Res. 1991; 25: 223-229
        • Inoue H.
        • Yamashita T.
        • Nozaki A.
        • et al.
        Effects of antiarrhythmic drugs on canine atrial flutter due to reentry: role of prolongation of refractory period and depression of conduction to excitable gap.
        J Am Coll Cardiol. 1991; 18: 1098-1104
        • Crijns H.J.
        • Van Gelder I.C.
        • Kingma J.H.
        • et al.
        Atrial flutter can be terminated by a class III antiarrhythmic drug but not by a class IC drug.
        Eur Heart J. 1994; 15: 1403-1408
        • Suttorp M.J.
        • Kingma J.H.
        • Jessurun E.R.
        • et al.
        The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm.
        J Am Coll Cardiol. 1990; 16: 1722-1727
        • Aljohani O.A.
        • Perry J.C.
        • Williams M.R.
        Intravenous sotalol for conversion of atrial flutter in infants.
        Heart Rhythm Case Rep. 2018; 4: 117-120
        • Tunca Sahin G.
        • Beattie R.B.
        • Uzun O.
        Favourable outcome for hydrops or cardiac failure associated with fetal tachyarrhythmia: a 20-year review.
        Cardiol Young. 2021; : 1-8https://doi.org/10.1017/S104795112100367X
        • Levy S.
        • Ricard P.
        Using the right drug: a treatment algorithm for regular supraventricular tachycardias.
        Eur Heart J. 1997; 18: C27-C32
        • Da Costa A.
        • Thevenin J.
        • Roche F.
        • et al.
        Results from the Loire-Ardeche-Drome-Isere-Puy-de-Dome (LADIP) trial on atrial flutter, a multicentric prospective randomized study comparing amiodarone and radiofrequency ablation after the first episode of symptomatic atrial flutter.
        Circulation. 2006; 114: 1676-1681
        • Diemberger I.
        • Massaro G.
        • Reggiani M.L.B.
        • et al.
        Outcomes with dronedarone in atrial fibrillation: what differences between Real-world practice and trials? A meta-analysis and meta-Regression analysis.
        Curr Pharm Des. 2017; 23: 944-951
        • Le Heuzey J.Y.
        • De Ferrari G.M.
        • Radzik D.
        • et al.
        A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study.
        J Cardiovasc Electrophysiol. 2010; 21: 597-605
        • Wilson H.
        • Patton D.
        • Moore Z.
        • et al.
        Comparison of dronedarone vs. flecainide in the maintenance of sinus rhythm, following electrocardioversion in adults with persistent atrial fibrillation: a systematic review and meta-analysis.
        Eur Heart J Cardiovasc Pharmacother. 2021; 7: 363-372
        • Singh B.N.
        • Singh S.N.
        • Reda D.J.
        • et al.
        Amiodarone versus sotalol for atrial fibrillation.
        N Engl J Med. 2005; 352: 1861-1872
        • Spinelli W.
        • Hoffman B.F.
        Mechanisms of termination of reentrant atrial arrhythmias by class I and class III antiarrhythmic agents.
        Circ Res. 1989; 65: 1565-1579
        • Boyden P.A.
        • Graziano J.N.
        Activation mapping of reentry around an anatomical barrier in the canine atrium: observations during the action of the class III agent, d-sotalol.
        J Cardiovasc Electrophysiol. 1993; 4: 266-279
        • Sung R.J.
        • Tan H.L.
        • Karagounis L.
        • et al.
        Intravenous sotalol for the termination of supraventricular tachycardia and atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled study. Sotalol Multicenter Study Group.
        Am Heart J. 1995; 129: 739-748
        • Vos M.A.
        • Golitsyn S.R.
        • Stangl K.
        • et al.
        Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.
        Heart. 1998; 79: 568-575
        • Benditt D.G.
        • Williams J.H.
        • Jin J.
        • et al.
        Maintenance of sinus rhythm with oral d,l-sotalol therapy in patients with symptomatic atrial fibrillation and/or atrial flutter. d,l-Sotalol Atrial Fibrillation/Flutter Study Group.
        Am J Cardiol. 1999; 84: 270-277
        • Chandler S.F.
        • Chu E.
        • Whitehill R.D.
        • et al.
        Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population.
        Heart Rhythm. 2020; 17: 984-990
        • Doggrell S.A.
        • Hancox J.C.
        Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation.
        Expert Opin Investig Drugs. 2005; 14: 655-669
        • Buchanan L.V.
        • LeMay R.J.
        • Walters R.R.
        • et al.
        Antiarrhythmic and electrophysiologic effects of intravenous ibutilide and sotalol in the canine sterile pericarditis model.
        J Cardiovasc Electrophysiol. 1996; 7: 113-119
        • Buchanan L.V.
        • Turcotte U.M.
        • Kabell G.G.
        • et al.
        Antiarrhythmic and electrophysiologic effects of ibutilide in a chronic canine model of atrial flutter.
        J Cardiovasc Pharmacol. 1993; 22: 10-14
        • Ellenbogen K.A.
        • Stambler B.S.
        • Wood M.A.
        • et al.
        Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.
        J Am Coll Cardiol. 1996; 28: 130-136
        • Kafkas N.V.
        • Patsilinakos S.P.
        • Mertzanos G.A.
        • et al.
        Conversion efficacy of intravenous ibutilide compared with intravenous amiodarone in patients with recent-onset atrial fibrillation and atrial flutter.
        Int J Cardiol. 2007; 118: 321-325
        • Sun J.L.
        • Guo J.H.
        • Zhang N.
        • et al.
        Clinical comparison of ibutilide and propafenone for converting atrial flutter.
        Cardiovasc Drugs Ther. 2005; 19: 57-64
        • Stambler B.S.
        • Wood M.A.
        • Ellenbogen K.A.
        Antiarrhythmic actions of intravenous ibutilide compared with procainamide during human atrial flutter and fibrillation: electrophysiological determinants of enhanced conversion efficacy.
        Circulation. 1997; 96: 4298-4306
        • Mazza A.
        • Fera M.S.
        • Bisceglia I.
        • et al.
        Efficacy and safety of ibutilide vs. transoesophageal atrial pacing for the termination of type I atrial flutter.
        Europace. 2004; 6: 301-306
        • Caron M.F.
        • Kluger J.
        • Tsikouris J.P.
        • et al.
        Effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide.
        Pharmacotherapy. 2003; 23: 296-300
        • Patsilinakos S.
        • Christou A.
        • Kafkas N.
        • et al.
        Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent.
        Am J Cardiol. 2010; 106: 673-676
        • Shenasa F.
        • Shenasa M.
        Dofetilide: electrophysiologic effect, efficacy, and safety in patients with cardiac arrhythmias.
        Card Electrophysiol Clin. 2016; 8: 423-436
        • Falk R.H.
        • Pollak A.
        • Singh S.N.
        • et al.
        Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators.
        J Am Coll Cardiol. 1997; 29: 385-390
        • Norgaard B.L.
        • Wachtell K.
        • Christensen P.D.
        • et al.
        Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group.
        Am Heart J. 1999; 137: 1062-1069
        • Suttorp M.J.
        • Polak P.E.
        • van 't Hof A.
        • et al.
        Efficacy and safety of a new selective class III antiarrhythmic agent dofetilide in paroxysmal atrial fibrillation or atrial flutter.
        Am J Cardiol. 1992; 69: 417-419
        • Banchs J.E.
        • Wolbrette D.L.
        • Samii S.M.
        • et al.
        Efficacy and safety of dofetilide in patients with atrial fibrillation and atrial flutter.
        J Interv Card Electrophysiol. 2008; 23: 111-115
        • Ibrahim M.A.
        • Kerndt C.C.
        • Tivakaran V.S.
        Dofetilide.
        StatPearls, Treasure Island (FL)2022
        • Camm A.J.
        • Toft E.
        • Torp-Pedersen C.
        • et al.
        Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double-blind, placebo-controlled trial.
        Europace. 2012; 14: 804-809
        • Morales G.
        • Darrat Y.H.
        • Lellouche N.
        • et al.
        Use of adenosine to shorten the post ablation waiting period for cavotricuspid isthmus-dependent atrial flutter.
        J Cardiovasc Electrophysiol. 2017; 28: 876-881
        • Stiell I.G.
        • de Wit K.
        • Scheuermeyer F.X.
        • et al.
        2021 CAEP acute atrial fibrillation/flutter best practices checklist.
        CJEM. 2021; 23: 604-610
        • Riad F.S.
        • Waldo A.L.
        Revisiting an underrecognized strategy for rhythm management: hybrid therapy for patients who convert from atrial fibrillation to flutter on antiarrhythmic drugs.
        J Innov Card Rhythm Manag. 2019; 10: 3842-3847